1. Home
  2. FGBI vs KZIA Comparison

FGBI vs KZIA Comparison

Compare FGBI & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Guaranty Bancshares Inc.

FGBI

First Guaranty Bancshares Inc.

HOLD

Current Price

$8.68

Market Cap

134.1M

Sector

Finance

ML Signal

HOLD

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

HOLD

Current Price

$13.43

Market Cap

154.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FGBI
KZIA
Founded
1934
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.1M
154.5M
IPO Year
2014
2002

Fundamental Metrics

Financial Performance
Metric
FGBI
KZIA
Price
$8.68
$13.43
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$19.50
AVG Volume (30 Days)
14.5K
182.5K
Earning Date
04-27-2026
06-04-2026
Dividend Yield
0.44%
N/A
EPS Growth
N/A
N/A
EPS
0.31
N/A
Revenue
N/A
N/A
Revenue This Year
$567.70
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$26.16
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.31
$4.86
52 Week High
$11.02
$17.40

Technical Indicators

Market Signals
Indicator
FGBI
KZIA
Relative Strength Index (RSI) 34.79 56.49
Support Level $7.83 $11.39
Resistance Level $9.24 $17.40
Average True Range (ATR) 0.33 1.08
MACD -0.04 0.23
Stochastic Oscillator 13.08 51.92

Price Performance

Historical Comparison
FGBI
KZIA

About FGBI First Guaranty Bancshares Inc.

First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana through several banking facilities. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and, to a lesser extent, consumer and multifamily loans. The company is engaged in a single line of business as a financial institution, which provides a full range of banking, financial, and trust services to state, county, and local government entities, individuals, and small and commercial businesses.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: